腺苷5'-O-(2-硫代三磷酸酯) | 60478-94-6

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷酸
• 中文名称: 腺苷5'-O-(2-硫代三磷酸酯)
• 英文名称: Adenosin 5'-O-(2-thio)triphosphat
• 英文别名: ATPβS；adenosine 5'-O-(2-thiotriphosphate)；O^5'-(tetrahydroxy-2-thio-[1]triphosphoryl)-adenosine；[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl [hydroxy(phosphonooxy)phosphinothioyl] hydrogen phosphate
• CAS: 60478-94-6
• 化学式: C₁₀H₁₆N₅O₁₂P₃S
• 分子量: 523.251
• InChiKey: XGAOYVYIONYFMI-VWJVIAGJSA-N

物化性质

• 沸点：
  901.8±75.0 °C(Predicted)
• 密度：
  2.56±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -4
• 重原子数：
  31
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  294
• 氢给体数：
  7
• 氢受体数：
  17

反应信息

• 作为反应物：
  描述：

  chromium chloride hexahydrate 、 腺苷5'-O-(2-硫代三磷酸酯) 以 水 为溶剂， 以60%的产率得到β,gamma.-bidentate Cr(H2O)4ATPβS
  参考文献：
  名称：

  Synthesis and stereochemical analysis of exchange-inert chromium(III) complexes of adenosine 5'-O-(2-thiodiphosphate), adenosine 5'-O-(2-thiotriphosphate), and adenosine 5'-O-(3-thiotriphosphate). Generation of a new class of chiral enzyme active site probes

  摘要：

  DOI：

  10.1021/ja00211a040

文献信息

• NOVEL COMPOUND, PRODUCTION METHOD THEREFOR, AND APPLICATION THEREFOR
  申请人：TOKYO UNIVERSITY OF PHARMACY & LIFE SCIENCES

  公开号：US20160304459A1

  公开（公告）日：2016-10-20

  [Problems] To provide a novel peptide synthesis technique that is completely different than heretofore, and to provide a novel compound that enables the synthesis/creation of a novel artificial functional protein and the synthesis/creation of a novel functional peptide, as well as a method for producing the same. [Solution] A compound represented by formula (I) or a salt thereof.

  【问题】提供一种与以往完全不同的新型肽合成技术，并提供一种能够合成/创造新型人工功能蛋白和新型功能肽的新型化合物，以及生产这些化合物的方法。【解决方案】由式（I）表示的化合物或其盐。
• Chromium complex with insulin-like activity
  申请人：Hwang L. David

  公开号：US20060105984A1

  公开（公告）日：2006-05-18

  A chromium complex for use in treating metabolic disorders, particularly Type 1 and Type 2 diabetes.

  一种铬配合物，用于治疗代谢紊乱，特别是1型和2型糖尿病。
• Primer, primer set, and nucleic acid amplification method and mutation detection method using the same
  申请人：Hayashizaki Yoshihide

  公开号：US20080227104A1

  公开（公告）日：2008-09-18

  The present invention provides a primer that effectively can detect, for example, the double helix structure of a nucleic acid. The primer is a labeled nucleic acid containing at least one structure represented by the following formula (16), where B is an atomic group having a nucleobase skeleton, E is an atomic group having a deoxyribose skeleton, a ribose skeleton, or a structure derived from either one of them, or an atomic group having a peptide structure or a peptoid structure, and Z 11 and Z 12 are each an atomic group that exhibits fluorescence and are identical to or different from each other.

  本发明提供了一种引物，可以有效地检测核酸的双螺旋结构，例如。该引物是一种带标记的核酸，其中至少包含下式（16）所表示的一个结构，其中B是具有核苷酸骨架的原子团，E是具有脱氧核糖骨架，核糖骨架或从它们中的任何一个派生的结构，或具有肽结构或肽酰结构的原子团，而Z11和Z12是各自表现出荧光的原子团，它们相同或不同。
• METHOD FOR ASSESSING EFFICACY OF COMBINATION CHEMOTHERAPY, AND PROGRAM AND DEVICE FOR ASSESSING THE SAME
  申请人：SUMINAKA Chihiro

  公开号：US20120278000A1

  公开（公告）日：2012-11-01

  A method for assessing an efficacy of combination chemotherapy, comprising: a first obtaining process for obtaining a specific activity value of Cyclin Dependent Kinase (CDK) 1 and a specific activity value of CDK2 in a biological sample including a carcinoma cell collected from a cancer patient; a second obtaining process for obtaining a GSTπ expression level in the biological sample; and an assessment process for assessing the efficacy of the combination chemotherapy on the cancer patient based on the specific activity values of CDK1 and CDK2 obtained in the first obtaining process and the GSTπ expression level obtained in the second obtaining process.

  一种评估联合化疗疗效的方法，包括：第一获取过程，用于获取从癌症患者采集的生物样本中的癌细胞中的Cyclin Dependent Kinase（CDK）1的特定活性值和CDK2的特定活性值；第二获取过程，用于获取生物样本中的GSTπ表达水平；以及评估过程，根据第一获取过程中获取的CDK1和CDK2的特定活性值以及第二获取过程中获取的GSTπ表达水平评估联合化疗对癌症患者的疗效。
• METHOD FOR DETERMINING SENSITIVITY OF TUMOR CELLS TO TYROSINE KINASE INHIBITOR AND COMPUTER PROGRAM PRODUCT
  申请人：KAWAI Masaaki

  公开号：US20110318768A1

  公开（公告）日：2011-12-29

  The present invention provides a method for determining sensitivity of the tumor cells to an EGFR and/or HER 2 inhibitor by evaluating inhibitory capacity of an Src inhibitor in a sample for measuring tyrosine kinase activity which is prepared from a biological sample containing tumor cells, a computer program and a method for determining effectiveness.

  本发明提供了一种方法，通过评估样本中Src抑制剂的抑制能力，测量来自含有肿瘤细胞的生物样本的酪氨酸激酶活性，以确定肿瘤细胞对EGFR和/或HER2抑制剂的敏感性，以及一种用于确定有效性的计算机程序和方法。